tbuckley/cabot-search huggingface dataset:
P12-7 A MSI-H mutational advanced gastric cancer case with Bulky N treated by pembrolizumab as a first-line therapy
Authors: K. Kobayashi, K. Takemori, H. Yamasaki, S. Kobayashi, T. Miyoshi, T. Kosaka, Y. Inoue, H. Matsushima, S. Kuba, M. Morita, S. Okada, Toshiyuki Adachi, T. Hara, H. Imamura, M. Yamashita, K. Matsuguma, A. Soyama, Tomohiko Adachi, K. Kanetaka, S. Eguchi
Journal: Annals of Oncology (2024)
A sub-study of the POISE-3 randomized trial examined effects of a perioperative hypotension-avoidance strategy versus a hypertension-avoidance strategy on the risk of acute kidney injury
Authors: Amit X Garg, Maura Marcucci, Meaghan S Cuerden, Jessica M Sontrop, Thomas W Painter, Vladimir Lomivorotov, Daniel I Sessler, Matthew T V Chan, Flavia K Borges, Kate Leslie, Emmanuelle Duceppe, Chirag R Parikh, Pavel Roshanov, María José Martínez-Zapata, Chew Yin Wang, Denis Xavier, Sergey Efremov, Giovanni Landoni, Ydo V Kleinlugtenbelt, Wojciech Szczeklik, Denis Schmartz, Christian S Meyhoff, Timothy G Short, Mohammed Amir, David Torres, Maria Wittmann, Ameen Patel, Kurt Ruetzler, Joel L Parlow, Raja Jayaram, Carisi A Polanczyk, Edith Fleischmann, Vikas Tandon, Sergey V Astrakov, David Conen, William Ka Kei Wu, Chao Chia Cheong, Sabry Ayad, Mikhail Kirov, Miriam de Nadal, Valery V Likhvantsev, Pilar Paniagua, Hector J Aguado, Sandra N Ofori, Jessica Vincent, Ingrid Copland, Kumar Balasubramanian, Bruce M Biccard, Sadeesh Srinathan, Samandar Ismoilov, Michael Ke Wang, Andrea Kurz, Emilie P Belley-Cote, Keyur Bhatt, John Eikelboom, Peter Gross, Andre Lamy, Michael McGillion, William McIntyre, Toby Richards, Jessica Spence, Thomas Van Helder, Richard Whitlock, Pj Devereaux
Journal: Kidney International (2024)
P2-1 Real-world clinical outcomes of nivolumab as a second- or later-line therapy for esophageal squamous cell carcinoma
Authors: M. Ohsawa, Y. Hamai, M. Emi, T. Kurokawa, T. Yoshikawa, R. Hirohata, N. Kitasaki, M. Okada
Journal: Annals of Oncology (2024)
P45-3 Efficacy and safety of TS-ONE in advanced non-small cell lung cancer in Thailand: a multicenter retrospective study
Authors: K. Maneenil, K. Korphaisarn, N. Prasongsook, C. Vinayanuwattikun, P. Sunraweravong, J. Chindaprasirt, V. Sriuranpong, C. Akewanlop, T. Baisamut
Journal: Annals of Oncology (2024)
P88-2 The association of XRCC1 rs25487 polymorphism with luminal and non-luminal breast cancer subtype in Bali
Authors: P. Wulandari, A. Indrakusuma, I. Sadeva, I. Kusuma, I. Supadmanaba, D. Wihandani, P. Adiputra
Journal: Annals of Oncology (2024)
P51-8 Vitamin D3 and Lysiphyllum strychnifolium extract are immunomodulator in colorectal carcinoma-bearing models
Authors: S. Sukprasert, N. Kuendee, A. Naladta, T. Yimsoo, W. Yingmema, A. Ariyachayut, W. Treesuppharat, R. Deenonpoe, K. Pansuksan, T. Kulsirirat, K. Sathirakul, J. Daduang
Journal: Annals of Oncology (2024)
MO62-2 Efficacy and tolerability of KEYNOTE-522 regimen for Japanese population: a single institute retrospective study
Authors: Y. Aoyama, Y. Ozaki, R. Kizawa, S. Kawai, M. Kurata, T. Maeda, K. Yoshida, N. Yamashita, M. Nishimura, M. Hosonaga, I. Fukada, F. Hara, T. Kobayashi, T. Takano, T. Ueno
Journal: Annals of Oncology (2024)
O14-5 Anticoagulation for distal deep venous thrombosis in cancer patients; a post-hoc analysis from PROVE-emboli study
Authors: T. Nose, Y. Imamura, S. Ohata, K. Mori, K. Otui, S. Kimbara, Y. Nagatani, T. Koyama, Y. Funakoshi, N. Kiyota, H. Minami
Journal: Annals of Oncology (2024)
MO32-1 Assessing the impact of comprehensive genome profiling in clinical practice: single-center observational study in Japan
Authors: N. Sugimoto, K. Kunimasa, T. Yamasaki, D. Sakai, F. Fujisawa, T. Inoue, K. Honma, Y. Kukita, Y. Yamaguchi, M. Kitasaka, T. Wakamatsu, S. Yamamoto, T. Hayashi, S. Mabuchi, J. Okuno, M. Urabe, Y. Kai, T. Kawamura, K. Nishimura
Journal: Annals of Oncology (2024)
O9-5 Efficacy of eribulin therapy in patients with advanced adenoid cystic carcinoma receiving platinum-based chemotherapy
Authors: T. Sanomachi, T. Shimoi, Y. Kojima, A. Kawachi, H. Sumiyoshi Okuma, M. Hoshino, M. Ito, A. Saito, S. Kita, A. Maejima, T. Nishikawa, K. Sudo, T. Mori, K. Yonemori
Journal: Annals of Oncology (2024)
PS1-3 RELAY: final overall survival with erlotinib+ramucirumab or placebo in untreated, EGFR-mutated metastatic NSCLC (mNSCLC)
Authors: K. Nakagawa, E.B. Garon, M. Nishio, T. Seto, K. Nishio, K. Kasahara, K. Nishino, M. Satouchi, K. Yoh, H. Hayashi, S. Enatsu, B. Frimodt-Moller, T. Matsui, S.C. Varughese, C. Visseren-Grul, M. Reck
Journal: Annals of Oncology (2024)
MO53-6 Impact of prior anticancer therapy on tumor mutational burden in patients with metastatic breast cancer
Authors: K. Baba, H. Nakajima, K. Kusuhara Mamishin, H. Sato, N. Takahashi, T. Nakao, C. Funasaka, C. Kondoh, K. Harano, N. Matsubara, A. Hosono, Y. Naito, S. Mimaki, T. Kawasaki, K. Tuchihara, T. Mukohara
Journal: Annals of Oncology (2024)
MO50-3 TCOG T3221 study: the registry of genetic alterations of Taiwan biliary tract cancer
Authors: N. Chiang, C. Hsu, J. Chen, M. Dai, L. Bai, C. Yen, T. Wang, Y. Hsieh, J. Lin, T. Chiu, H. Cheng, Y. Yang, C. Hsiao, L. Chen, M. Chen
Journal: Annals of Oncology (2024)
O18-5 Sacituzumab govitecan in Japanese patients with metastatic triple-negative breast cancer: phase 2 results of ASCENT J02
Authors: Y. Naito, S. Nakamura, N. Kawaguchi, T. Ishida, T. Nakayama, Y. Yamamoto, N. Masuda, K. Matsumoto, T. Kogawa, K. Sudo, A. Shimomura, C. Lai, D. Zhang, Y. Iwahori, D. Gary, D. Huynh, H. Iwata
Journal: Annals of Oncology (2024)
PS2-2 Analysis of ctDNA changes in locally advanced rectal cancer that underwent neoadjuvant treatment - GALAXY trial
Authors: A. Hamabe, I. Takemasa, K. Ando, Y. Nakamura, S. Mishima, H. Yukami, K. Hirata, M. Miyo, N. Matsuhashi, M. Uemura, Y. Ide, Y. Takano, J. Adham, D. Kotani, H. Taniguchi, E. Oki, T. Kato, T. Yoshino
Journal: Annals of Oncology (2024)
MO50-7 Evaluation of preoperative chemotherapy and cancer genome therapy for intrahepatic cholangiocarcinoma in our hospital
Authors: T. Matsumoto, H. Hayashi, S. Yumoto, H. Miyamoto, Y. Adachi, K. Kanemitsu, T. Tajiri, T. Ofuchi, D. Ogawa, Y. Shiraishi, T. Takematsu, R. Itoyama, Y. Kitano, S. Nakagawa, K. Mima, H. Okabe, Y. Tanaka, H. Baba
Journal: Annals of Oncology (2024)
MO60-3 Aggregated analysis of integrated whole exome (WES) and whole transcriptome (WTS) sequencing in 1,000 cancer patients
Authors: K. Chernyshov, A. Love, K. Rumyantsev, V. Senichkin, G. Sagaradze, Z. Polyakova, Y. Shiotsu, P. Clayton, E. Postovalova, N. Kotlov, A. Ogloblina, A. Bagaev, N. Fowler
Journal: Annals of Oncology (2024)
MO30-2 Prognostic impact of AKAP8 expression in breast cancer patients
Authors: N. Matsumoto, A. Kato, Y. Wanifuchi, T. Fuzita, T. Asano, N. Horisawa, M. Mori, A. Isogai, R. Ogawa, T. Toyama
Journal: Annals of Oncology (2024)
MO53-1 Tumour suppressor microRNAs (200a, 200b, miR205 &amp; miR 145) and breast cancer stem cells in patients of breast carcinoma
Authors: S. Dwivedi, M. Khokhar, P. Pareek, J. Ram Vishnoi, P. Sharma, S. Misra
Journal: Annals of Oncology (2024)
O6-1 Post-hoc analysis of TRAEs observed in a phase 2 study of encorafenib + binimetinib in metastatic BRAF V600-mutated TC
Authors: S. Takahashi, M. Tahara, N. Kiyota, H. Imai, A. Nishiyama, S. Tamura, Y. Shimizu, S. Kadowaki, K. Ito, M. Toyoshima, Y. Hirashima, S. Ueno, H. Wakasawa, I. Sugitani
Journal: Annals of Oncology (2024)
O6-4 Impact of PIK3CA and cell cycle pathway alterations on durvalumab efficacy in head and neck squamous cell carcinoma
Authors: D. Kim, S. Lim, H. Kim, E. Kang, H. Ahn, Y. Lee, D. Sun, J. Kwon, S. Lee, H. Lee, M. Kim, B. Keam, K. Park, S. Shin, H. Yun
Journal: Annals of Oncology (2024)
O18-2 Second interim analysis of REIWA study (JBCRG-C07), observational study of gene panel testing in metastatic breast cancer
Authors: H. Tada, H. Masuda, Y. Adachi, T. Iwatani, Y. Uemoto, Y. Otani, Y. Kajiwara, D. Kitagawa, T. Kogawa, Y. Sagara, T. Shien, Y. Tanabe, M. Tanioka, F. Hara, H. Yasojima, M. Hattori, K. Yoshimura, H. Iwata, N. Masuda
Journal: Annals of Oncology (2024)
MO37-3 Construction of data for implementation of comprehensive cancer genome profiling using genome-guided system
Authors: Y. Sunakawa, H. Arai, H. Yamamoto, A. Motoyoshi, O. Migita, T. Ohara, N. Furuya, K. Imoto, S. Hettich, I. Avi Cemel, L. Kyjacova, M. Rauschendorf, Y. Yamano
Journal: Annals of Oncology (2024)
O15-5 COVID-19 in patients during treatment at the outpatient chemotherapy unit
Authors: S. Kinoshita, M. Takemoto, M. Asaoka, Y. Haraguchi, T. Adachi, T. Suzuki, T. Narita, M. Ri, T. Sanda, S. Iida, H. Komatsu
Journal: Annals of Oncology (2024)
O3-4 First-line tislelizumab plus chemotherapy in gastric/gastroesophageal junction cancer: RATIONALE-305 Asian Subgroup
Authors: K. Kato, Y. Bai, J. Shi, K. Lee, J. Wang, H. Pan, S. Rha, R. Zhang, H. Hirano, K. Yamaguchi, Z. Guo, Y. Ba, L. Yang, H. Tsukuda, Y. Xu, T. Sheng, S. Yang, L. Li, D. Oh, R. Xu
Journal: Annals of Oncology (2024)
MO25-2 Phase 1 study of tusamitamab ravtansine every 2 weeks with loading dose in Japanese patients with advanced solid tumors
Authors: S. Kadowaki, T. Yoshino, K. Yamazaki, Y. Narita, S. Mishima, T. Kawakami, H. Nakajima, T. Tanaka, K. Tada, N. Fagniez, K. Muro
Journal: Annals of Oncology (2024)
MO40-3 Impact of acquired RAS, BRAF and PIK3CA mutation at 8 weeks on the efficacy of anti- EGFR monoclonal antibodies in mCRC
Authors: T. Kudo, K. Kataoka, T. Yamada, K. Mori, M. Shiozawa, N. Takase, K. Ito, H. Eda, K. Kimura, J. Song, N. Matsuhashi, T. Miyasaka, J. Tajima, N. Beppu, Y. Oi, K. Yamazaki, M. Ikeda
Journal: Annals of Oncology (2024)
O17-5 Clinical impact of 18F-FDG-PET/CT in predicting ICI-induced ILD in patients with lung cancer
Authors: S. Watanabe, M. Yamazaki, N. Yanagimura, M. Arita, A. Ohtsubo, T. Tanaka, K. Nozaki, Y. Saida, R. Kondo, Y. Fuzawa, M. Tominaga, T. Yagi, H. Ishikawa, T. Kikuchi
Journal: Annals of Oncology (2024)
O15-2 Current status of distress screening among cancer patients: a survey of requirements in designated cancer care hospitals
Authors: J. Sakane, Y. Ito, M. Ota, I. Ueda, Y. Fujisaka, R. Rikitake, T. Watanabe, Y. Yamamoto, Y. Ichinose, M. Nino, M. Matsuki, T. Higashi, F. Wakao
Journal: Annals of Oncology (2024)
MO59-1 An investigator-initiated phase II trial of tirabrutinib in patients with relapsed or refractory secondary CNS lymphoma
Authors: W. Munakata, H. Goto, N. Fukuhara, H. Nagai, H. Arima, K. Kato, K. Kurishita, Y. Shuda, R. Isomura, Y. Ando, N. Iwaki, R. Sadachi, N. Okita, K. Izutsu
Journal: Annals of Oncology (2024)
O13-2 Raludotatug deruxtecan (R-DXd; DS-6000) in Japanese patients with ovarian cancer: subgroup analysis of a phase 1 study
Authors: K. Sudo, E.P. Hamilton, K. Harano, S. Kitano, K. Takehara, A. Philipovskiy, B. Rini, D.R. Spigel, J. Lin, Y. Okuda, A. Bensmaine, Y. Myobatake, K. Moore
Journal: Annals of Oncology (2024)
MO57-3 Effect of immunochemotherapy time-of-day infusion, sequence and interval on prognosis of advanced esophageal cancer
Authors: S. Huang, Z. Li, Z. Gao, S. Wang, J. Sun, H. Wu, J. Liu, P. M. K Tang, R. Chen, Y. Tang, X. Ben, J. Tang, H. Zhou, D. Zhang, L. Xie, G. Chen, G. Qiao
Journal: Annals of Oncology (2024)
MO41-6 Chemotherapy for metastatic or recurrent soft tissue sarcoma: real-world experience in a single institute
Authors: O. Maeda, T. Shimokata, A. Mitsuma, H. Urakawa, Y. Takano, C. Kondo, S. Furune, Y. Miyai, N. Torii, Y. Liang, S. Morita, M. Inoue, Y. Ando
Journal: Annals of Oncology (2024)
O5-2 WJOG (West Japan Oncology Group) Breast Cancer Consensus Meeting 2023
Authors: Y. Kimura, R. Watanuki, Y. Aoyama, H. Sakai, A. Shimomura, J. Tsurutani, S. Tokunaga, T. Mukohara, K. Matsumoto, T. Iwasa, Y. Ozaki, K. Nozawa, M. Terada, R. Kizawa, T. Takano
Journal: Annals of Oncology (2024)
MO45-4 New initiatives for urological cancer genome outpatient services at our hospital
Authors: M. Okawa, M. Wakai, M. Shuhara, A. Okubo, A. Sano, M. Mitsuda, N. Takai, H. Ozawa, R. Iwamoto, Y. Nagahama, H. Aoki, F. Yamabe, Y. Mitsui, H. Kobayashi, N. Tochigi, S. Ujiie, Y. Kikuchi, H. Hara, Y. Katagiri, K. Nakajima
Journal: Annals of Oncology (2024)
MO9-4 Palbociclib plus letrozole vs letrozole alone in ER+/HER2− advanced breast cancer: a systematic review and meta-analysis
Authors: M.Z. Sabran, C.E.O.L. Hutauruk, C.J. Budianto, N.B.S.A. Purushotama, J.V. Lee, M.G. Wibisono, A. Kurniawan, I. Huang
Journal: Annals of Oncology (2024)
MO39-1 Clinical utility of cancer gene panel testing from real-world data: focusing on discrepancies between CDx and CGP
Authors: Y. Okugawa, T. Kitajima, T. Fujiwara, J. Tsuboi, Y. Tono, K. Saito, T. Tamaru, I. Mochiki, H. Imai, T. Mizuno, Y. Toiyama
Journal: Annals of Oncology (2024)
O15-3 Osteoporosis treatment in cancer patients: insights and challenges from specialized facilities
Authors: H. Koyanagi, S. Tsujino, Y. Ishikawa, C. Sawamura, R. Motomura, K. Takahashi, J. Manabe, N. Kawaguchi, T. Yoshii, T. Gokita
Journal: Annals of Oncology (2024)
PS3-3 Clinical and biomarker data from a phase 1/2 trial of ifinatamab deruxtecan (I-DXd; DS-7300) in advanced solid tumors
Authors: T. Doi, M.R. Patel, T. Koyama, G.S. Falchook, C. Friedman, S.A. Piha-Paul, M. Gutierrez, M. Awad, A. Mattour, T. Satoh, S. Takahashi, T. Tsunoda, S. Kadowaki, Y. Watanabe, N. Okamoto, H. Goto, N. Yoshizuka, M. Qian, X. Qian, M. Johnson
Journal: Annals of Oncology (2024)
MO25-3 Safety and pharmacokinetics of tusamitamab ravtansine dosing Q3W in Japanese patients with advanced solid tumors
Authors: S. Mishima, K. Muro, K. Yamazaki, S. Kadowaki, Y. Kuboki, S. Hamauchi, Y. Aoki, S. Ohshima, K. Tada, N. Fagniez, T. Yoshino
Journal: Annals of Oncology (2024)
PS3-2 Final OS analysis from the phase 3 TROPiCS-02 study: sacituzumab govitecan in HR+/HER2− metastatic breast cancer
Authors: H.S. Rugo, A. Bardia, F. Marme, J. Cortes, P. Schmid, D. Loirat, O. Tredan, E. Ciruelos, F. Dalenc, P. Gomez Pardo, K.L. Jhaveri, R. Delaney, T. Valdez, O. Yoon, H. Wang, W. Verret, S.M. Tolaney
Journal: Annals of Oncology (2024)
PS3-1 Dato-DXd vs. chemotherapy for patients with inoperable/metastatic HR+/HER2− breast cancer: TROPION-Breast01 Asian subset
Authors: J. Tsurutani, M. Hattori, S. Im, S. Wang, Y. Lu, J. Sohn, Q. Zhang, Y. Park, K. Lee, Y. Ozaki, Z. Jiang, W. Chung, M. De Laurentiis, S. Pernas, L. Xu, S. Khan, N. Denduluri, B. Pistilli, A. Bardia, B. Xu
Journal: Annals of Oncology (2024)
MO42-5 A phase 2 study of intrapatient dose escalation of bi-weekly FTD/TPI plus BEV for colorectal cancer (E-BiTS study)
Authors: M. Wakabayashi, H. Taniguchi, S. Yuki, H. Takeda, S. Mitani, Y. Okumura, N. Akazawa, K. Yamaguchi, A. Makiyama, T. Kudo, C. Kudo, K. Mori, K. Muro
Journal: Annals of Oncology (2024)
MO6-1 Overall survival and safety of tebentafusp as potential treatment for patients with uveal melanoma: a systematic review
Authors: K. Aurelia Santoso, S. Kosayuz, W. Surya Atmaja, A. Irviani Ukhti Amalia, D. Ravinder Theodeus Subroto, A. Kurniawan
Journal: Annals of Oncology (2024)
MO42-6 Efficacy and safety of tipiracil combined with bevacizumab in metastatic colon cancer patients: a systematic review
Authors: H. Glory, J.A. Liem, M.F. Wiryadipura, G.R. Wirawan, E. Samudra, B.S. Luih, P. Wirajaya, K. Colfoort, G.S. Suwongto, A. Kurniawan, I. Huang
Journal: Annals of Oncology (2024)
MO38-6 The utility of circulating tumor DNA in gastrointestinal stromal tumor – a pooled analysis of SCRUM-Japan trials
Authors: T. Hashimoto, Y. Nakamura, Y. Komatsu, N. Takahashi, N. Okano, C. Morizane, K. Ohtsubo, T. Ohta, E. Oki, T. Nishina, H. Yasui, H. Kawakami, T. Esaki, N. Machida, A. Doi, S. Boku, T. Kudo, T. Fujisawa, H. Bando, T. Yoshino
Journal: Annals of Oncology (2024)
MO50-6 Characterization of patients with advanced biliary tract cancer by KRAS alteration subtypes
Authors: T. Shibuki, Y. Nakamura, M. Ueno, M. Furukawa, Y. Kawamoto, S. Itoh, K. Umemoto, K. Sudo, T. Satoh, N. Mizuno, A. Asagi, N. Okano, S. Shimizu, K. Ohtsubo, T. Matsumoto, T. Fujisawa, H. Bando, T. Yoshino, C. Morizane, M. Ikeda
Journal: Annals of Oncology (2024)
MO48-5 Third-line chemotherapy for recurrent/refractory rhabdomyosarcoma in adults: a single-center retrospective study
Authors: T. Imai, T. Shimoi, Y. Kojima, A. Kawachi, H. Okuma Sumiyoshi, M. Hoshino, M. Ito, A. Saito, S. Kita, A. Maejima, T. Nishikawa, K. Sudo, K. Yonemori
Journal: Annals of Oncology (2024)
MO48-1 C-reactive protein as prognostic factor in soft tissue sarcoma: a systematic review and meta-analysis
Authors: A.I. Chandra, Y. Lim, A.M. Noersamsjah, I. Kusuma, H.S. Koerniawan, J.J. Wibisono, A. Kurniawan
Journal: Annals of Oncology (2024)
MO40-1 Predictors for m-FOLFOXIRI plus cetuximab in RAS/BRAF wild-type and left-sided mCRC: the DEEPER trial (JACCRO CC-13)
Authors: S. Natsume, T. Sekikawa, A. Takagane, K. Sawada, H. Bando, T. Yamada, H. Nakayama, Y. Uchima, T. Shiraishi, J. Kizaki, T. Furuya, M. Takeuchi, W. Ichikawa, M. Fujii, Y. Sunakawa, A. Tsuji
Journal: Annals of Oncology (2024)
MO5-4 Clinical utility of upfront comprehensive genomic profiling for the treatment of advanced pancreatic cancer
Authors: E. So, H. Hayashi, K. Shimozaki, Y. Sato, S. Horie, S. Kishimoto, A. Chida, Y. Saito, K. Tsugaru, K. Hirata, H. Nishihara, T. Kanai, Y. Hamamoto
Journal: Annals of Oncology (2024)
MO20-6 Real-world treatment patterns and outcomes in Japanese patients with large B-cell lymphoma after two systemic therapies
Authors: L. Liao, A. Chhibber, G. Zhang, J. Kim, A. Keshishian, S. Chung, S. Shrestha, H. Ando, K. Takaura, M. Sakai, A. Mutebi
Journal: Annals of Oncology (2024)
MO1-1 6y update of 1L nivolumab + ipilimumab (N+I) in metastatic (m) NSCLC, including in Japanese pts, from CheckMate 227
Authors: M. Nishio, S.S. Ramalingam, T. Ciuleanu, R. Bernabe Caro, H. Mizutani, J. Lee, C. Audigier-Valette, R. Sangha, L. Urban, J.A. Burgers, A. Pluzanski, K. Hyeong Lee, B. Zurawski, M. Schenker, S. Peters, L.G. Paz-Ares, H. Borghaei, K.J. O'Byrne, J.R. Brahmer, R.G. Gupta, J. Bushong, L. Li, Y. Yuan, S.I. Blum, M. Reck
Journal: Annals of Oncology (2024)
MO24-1 Outcomes of adjuvant therapy with anti-PD-1 antibody for mucosal melanoma
Authors: M. Okumura, D. Ogata, K. Namikawa, E. Nakano, G. Omura, Y. Honma, K. Ishiyama, S. Tsukamoto, Y. Matsui, M. Ishikawa, S. Suzuki, Y. Kanemitsu, H. Daiko, S. Yoshimoto, K. Kato, N. Yamazaki
Journal: Annals of Oncology (2024)
MO35-3 A phase II study of weekly carboplatin and concurrent radiotherapy for locally advanced NSCLC in elderly patients
Authors: T. Harada, H. Ishii, S. Takemoto, Y. Hisamatsu, H. Saito, Y. Yoneshima, K. Komiya, K. Kashiwabara, S. Kusuhara, T. Ogawa, H. Takeoka, K. Saruwatari, K. Ito, Y. Tsuchiya, K. Mizuno, Y. Shioyama, T. Sasaki, T. Shimose, I. Okamoto
Journal: Annals of Oncology (2024)
MO42-1 FOLFOXIRI-Bev as first-line treatment in patients with metastatic colorectal cancer: a systematic review of RCT
Authors: B. Stephanie Luih, E. Samudra, G. Sonia Suwongto, H. Glory, K. Colfoort, P. Wirajaya, A. Kurniawan
Journal: Annals of Oncology (2024)
MO18-6 Prospective changes in financial toxicity and health-related quality of life in patients with gynecologic cancer
Authors: Y. Kajimoto, S. Suzuki, M. Mori, K. Nakao, A. Azuma, S. Nagao, T. Shibutani, T. Koyanagi, I. Kohara, S. Tamaki, M. Yabuki, L. Teng, K. Honda, A. Igarashi
Journal: Annals of Oncology (2024)
MO15-2 Establishing real-world data on actual advanced gastric cancer therapy using CyberOncology: a feasibility study
Authors: N. Machida, S. Kadowaki, T. Nishina, Y. Sunakawa, T. Maekita, S. Matsumoto, M. Nishioka, T. Goto, Y. Hamamoto, H. Yasui, M. Furuta, T. Kajiwara, H. Arai, M. Kitano, F. Nagashima, R. Kawabe, M. Okada, M. Muto, K. Muro
Journal: Annals of Oncology (2024)
MO38-2 Clinicopathological features of early-onset colorectal cancer
Authors: Y. Okagawa, K. Hanada, S. Hirokawa, Y. Tomita, M. Yoshida, T. Minagawa, K. Morita, K. Yane, H. Ihara, T. Sumiyoshi, M. Hirayama, H. Kondo
Journal: Annals of Oncology (2024)
MO25-6 Hypofractionated post-operative radiation in head and neck cancers (HNC): a preliminary account of locoregional control
Authors: A. Ghosh, A. Dagar, A. Amariyil, Y. KN, S. Mallick, J. Raj, S. Hazarika, S. Panda, R. Kumar, J. Sharma, A. Mishra, A. Thakar, S. Deo, S. Bhaskar, D. Sharma, A. Sharma
Journal: Annals of Oncology (2024)
O10-4 Current status and future of patient and public involvement in pancreatic cancer clinical practice guidelines revision
Authors: Y. Sakamoto, T. Okusaka, K. Hanada, M. Nakamura, M. Mori, M. Fujimori, Y. Shimizu, A. Okumura, K. Shima, Y. Majima, S. Furutani, S. Osada, M. Yoshida, Y. Takeyama
Journal: Annals of Oncology (2024)
MO34-3 The efficacy of combined EGFR-TKI plus VEGF inhibitor/cytotoxic therapy for PD-L1-positive EGFR-mutant NSCLC: NJLCG2202
Authors: Y. Kawashima, M. Inomata, R. Saito, D. Morinaga, H. Nogawa, M. Satou, Y. Suzuki, S. Yanagisawa, T. Kikuchi, D. Jingu, N. Yoshimura, T. Harada, E. Miyauchi
Journal: Annals of Oncology (2024)
MO20-2 Long-term follow-up shows epcoritamab drives deep, durable responses in relapsed/refractory follicular lymphoma (R/R FL)
Authors: K. Izutsu, D. Akahane, T. Toubai, T. Saito, Y. Mishima, T. Fujisaki, T. Kitawaki, T. Kumode, Y. Suehiro, K. Ishitsuka, R. Conlon, H. Noguchi, J. Buchbjerg, E. Favaro, N. Fukuhara
Journal: Annals of Oncology (2024)
MO12-6 Efficacy and safety of venetoclax and azacytidine for acute myeloid leukemia: a retrospective, single-center study
Authors: Y. Yamaguchi, D. Hirano, R. Minami, S. Hirano, Y. Suzuki, N. Imahashi, T. Adachi, H. Nagai, H. Iida
Journal: Annals of Oncology (2024)
P91-5 A single-center retrospective study of 14 patients using olaparib for metastatic breast cancer
Authors: T. Ishiba, M. Nara, C. Saita, H. Kamio, K. Miyahara, N. Iwamoto, R. Hashimoto, N. Nakatsugawa, M. Adachi, Y. Kumaki, G. Oda, T. Aruga, M. Toi
Journal: Annals of Oncology (2024)
MO63-6 Utility of comprehensive genomic profiling for malignant breast tumors – a single institutional experience
Authors: Y. Ozaki, Y. Takano, T. Kikumori, D. Takeuchi, M. Iwase, T. Ichikawa, T. Inaishi, I. Soeda, K. Sugino, Y. Akita, M. Asai, M. Yamamoto, G. Inaguma, N. Torii, N. Masuda
Journal: Annals of Oncology (2024)
P105-5 Efficacy of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma: a systematic review
Authors: C.J. Budianto, M.Z. Sabran, C.E.O.L. Hutauruk, N.B.S.A. Purushotama, A. Kurniawan, I. Huang
Journal: Annals of Oncology (2024)
MO10-4 Pretreatment eosinophil counts as a predictive biomarker in NSCLC patients treated with immune checkpoint inhibitors
Authors: E. Takeuchi, K. Kondo, Y. Okano, S. Ichihara, M. Kunishige, N. Kadota, H. Machida, N. Hatakeyama, K. Naruse, H. Ogino, H. Nokihara, T. Shinohara, Y. Nishioka
Journal: Annals of Oncology (2024)
P109-7 Defining a group of oligometastatic nasopharyngeal carcinoma patients with improved survival outcomes
Authors: W. Kee, M. Ang, E. Tan, D.W.T. Lim, D.S.W. Tan, Q. Ng, K. Fong, T.W.K. Tan, Y. Soong, F. Wang, S.S. Poh, J.T.S. Wee, K. Sommat, Y. Teh
Journal: Annals of Oncology (2024)
P114-5 Gemcitabine combination vs gemcitabine alone in platinum-resistant/refractory ovarian cancer: a systematic review
Authors: M. Geraldi Lokanata, J.H. Wijaya, M. Zuhriansyah Sabran, M.L.R. Lokanata, A.O. Djohansjah
Journal: Annals of Oncology (2024)
MO53-4 Sacituzumab Govitecan-Hziy as treatment in metastatic breast cancer: a systematic review and meta-analysis of RCTs
Authors: J. Andrina Liem, F. Wijovi, B.E. Herijanto, J.L. Gracia, N.D.D. Rustiadi, L. Julian, E.C.K. Sucahyo, T.M. Argo, H. Glory, J.O. Sugianto, C.F. Jhoputri, K.Y. Rubismo, G.R. Wirawan, A. Kurniawan, I. Huang
Journal: Annals of Oncology (2024)
P109-9 Efficacy of pembrolizumab-chemotherapy vs. cetuximab-chemotherapy in head and neck squamous cell carcinoma
Authors: T. Jeanice, C.M.A. Gunawan, E.C. Liem, Y.R. Gunawan, I.D. Evangelista, G.M. Sukendro, A. Kurniawan, I. Huang
Journal: Annals of Oncology (2024)
P113-3 Comparison between HPV test and liquid-based cytology for cervical cancer detection: a systematic review and meta-analysis
Authors: C.A. Sutedja, M.Z. Sabran, E. Budiarti, C.E.O.L. Hutauruk, M.D. Sembiring, Y.A.P. Ontowirjo, A. Kurniawan
Journal: Annals of Oncology (2024)